ziltivekimab

News

Novo Nordisk's IL-6 inhibitor ziltivekimab has failed the phase 3 ZEUS trial in heart disease, denting its bid to expand into new therapeutic areas.

News

There are rumours that the first pharma 'mega-merger' for several years – between AstraZeneca and Bristol Myers Squibb – is under discussion.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.